Wordt geladen...
The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma
Doxorubicin (DOX) is one of the widely used chemotherapeutic drugs for the treatment of human osteosarcoma (OS). However, acquisition of DOX resistance is common in patients with OS, leading to local and distant failure. In this study, we demonstrate that survivin expression is significantly upregul...
Bewaard in:
| Gepubliceerd in: | Int J Clin Exp Med |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
e-Century Publishing Corporation
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4694298/ https://ncbi.nlm.nih.gov/pubmed/26770398 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|